HAE, TWST Stocks Jump To Over 5-Year Highs – What’s Driving The Gains Today?
Haemonetics (HAE) and Twist Bioscience (TWST) shares reached over 5-year highs. HAE rose 2% due to a renewed deal with CSL Plasma, with Citi upgrading it to 'Buy' and raising its target to $123. TWST surged 11% following its AI drug discovery partnership with Eli Lilly's TuneLab, with Leerink raising its target to $160.
How this was made
The 30-second read
Why it matters
Both companies experience immediate price appreciation, with analysts projecting earnings upside and long‑term growth from AI integration.
Market read
The announcements drive short‑term bullish moves and suggest longer‑term sector momentum for AI‑enabled biotech and medical‑technology equipment.
What to watch
Potential supply‑chain constraints for Twist’s antibody testing reagents and regulatory scrutiny of AI‑driven drug pipelines.
Background
The article reports fresh analyst upgrades and new commercial agreements that are the first public disclosures of these developments.
Ticker impact
Haemonetics announced a renewed non‑exclusive deal with CSL Plasma, prompting a 2% price rise and a Citi upgrade to Buy.
Potential upside of 5‑10% if CSL business recovers as projected.
The agreement restores a former major customer and is backed by an analyst upgrade with a higher price target.
Twist Bioscience secured an AI‑driven drug discovery partnership with Eli Lilly’s TuneLab platform, driving an 11% surge.
Further upside of 8‑12% if partnership yields expected AI‑drug pipeline benefits.
The new AI partnership is a fresh catalyst, reinforced by a Leerink price‑target raise.
Market effects
Both deals highlight growing demand for AI‑enabled biotech services and plasma collection technology, potentially benefiting the broader life‑science equipment and genomics sectors.
Positive sentiment for U.S. biotech and medical‑technology stocks, with modest spillover to related ADRs.
Shows increasing integration of AI in drug discovery worldwide, a trend likely to influence global biotech valuations.
Counterpoint
If CSL Plasma’s usage remains limited or AI partnership fails to deliver commercial breakthroughs, the price gains could be short‑lived.
Key entities
- AnalystCiti
Upgraded Haemonetics to Buy and raised price target.
- AnalystLeerink
Raised Twist Bioscience’s price target and highlighted AI opportunity.
- PartnerCSL Plasma
Entered renewed supply agreement with Haemonetics.
- PartnerEli Lilly TuneLab
Partnered with Twist Bioscience for AI‑driven antibody data.
